Literature DB >> 21144847

KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1.

Jeremy A Goettel1, Dongchun Liang, Valda C Hilliard, Karen L Edelblum, Matthew R Broadus, Kathleen L Gould, Steven K Hanks, D Brent Polk.   

Abstract

The extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway is a highly conserved signaling pathway that regulates diverse cellular processes including differentiation, proliferation, and survival. Kinase suppressor of Ras-1 (KSR1) binds each of the three ERK cascade components to facilitate pathway activation. Even though KSR1 contains a C-terminal kinase domain, evidence supporting the catalytic function of KSR1 remains controversial. In this study, we produced recombinant wild-type or kinase-inactive (D683A/D700A) KSR1 proteins in Escherichia coli to test the hypothesis that KSR1 is a functional protein kinase. Recombinant wild-type KSR1, but not recombinant kinase-inactive KSR1, underwent autophosphorylation on serine residue(s), phosphorylated myelin basic protein (MBP) as a generic substrate, and phosphorylated recombinant kinase-inactive MAPK/ERK kinase-1 (MEK1). Furthermore, FLAG immunoprecipitates from KSR1(-/-) colon epithelial cells stably expressing FLAG-tagged wild-type KSR1 (+KSR1), but not vector (+vector) or FLAG-tagged kinase-inactive KSR1 (+D683A/D700A), were able to phosphorylate kinase-inactive MEK1. Since TNF activates the ERK pathway in colon epithelial cells, we tested the biological effects of KSR1 in the survival response downstream of TNF. We found that +vector and +D683A/D700A cells underwent apoptosis when treated with TNF, whereas +KSR1 cells were resistant. However, +KSR1 cells were sensitized to TNF-induced cell loss in the absence of MEK kinase activity. These data provide clear evidence that KSR1 is a functional protein kinase, MEK1 is an in vitro substrate of KSR1, and the catalytic activities of both proteins are required for eliciting cell survival responses downstream of TNF. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144847      PMCID: PMC3038243          DOI: 10.1016/j.yexcr.2010.11.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  71 in total

1.  B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway.

Authors:  P Erhardt; E J Schremser; G M Cooper
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  Characterization of a domain that transiently converts class 2 DYRKs into intramolecular tyrosine kinases.

Authors:  Ross Kinstrie; Nathan Luebbering; Diego Miranda-Saavedra; Gary Sibbet; Jingfen Han; Pamela A Lochhead; Vaughn Cleghon
Journal:  Sci Signal       Date:  2010-03-02       Impact factor: 8.192

3.  The MAPK scaffold kinase suppressor of Ras is involved in ERK activation by stress and proinflammatory cytokines and induction of arthritis.

Authors:  Angela M Fusello; Laura Mandik-Nayak; Fei Shih; Robert E Lewis; Paul M Allen; Andrey S Shaw
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

4.  Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.

Authors:  Maureen O Ripple; Sahana Kalmadi; Alan Eastman
Journal:  Breast Cancer Res Treat       Date:  2005-09       Impact factor: 4.872

5.  Interactions of c-Raf-1 with phosphatidylserine and 14-3-3.

Authors:  R A McPherson; A Harding; S Roy; A Lane; J F Hancock
Journal:  Oncogene       Date:  1999-07-01       Impact factor: 9.867

6.  Kinase suppressor of Ras forms a multiprotein signaling complex and modulates MEK localization.

Authors:  S Stewart; M Sundaram; Y Zhang; J Lee; M Han; K L Guan
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

7.  Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation.

Authors:  Fang Yan; Sutha K John; Guinn Wilson; David S Jones; M Kay Washington; D Brent Polk
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 8.  Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Authors:  P Rutgeerts; G Van Assche; S Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

9.  Kinase suppressor of Ras transphosphorylates c-Raf-1.

Authors:  Mohammad Zafrullah; Xianglei Yin; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Biochem Biophys Res Commun       Date:  2009-09-17       Impact factor: 3.575

Review 10.  Emerging roles of pseudokinases.

Authors:  Jérôme Boudeau; Diego Miranda-Saavedra; Geoffrey J Barton; Dario R Alessi
Journal:  Trends Cell Biol       Date:  2006-08-01       Impact factor: 20.808

View more
  13 in total

Review 1.  Signal control through Raf: in sickness and in health.

Authors:  Jihan K Osborne; Elma Zaganjor; Melanie H Cobb
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

2.  Tyr728 in the kinase domain of the murine kinase suppressor of RAS 1 regulates binding and activation of the mitogen-activated protein kinase kinase.

Authors:  Claudia Sibilski; Thomas Mueller; Laxmikanth Kollipara; René P Zahedi; Ulf R Rapp; Thomas Rudel; Angela Baljuls
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

Review 3.  Regulation of RAF protein kinases in ERK signalling.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05       Impact factor: 94.444

4.  Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.

Authors:  Marsha D Wallace; Adam D Pfefferle; Lishuang Shen; Adrian J McNairn; Ethan G Cerami; Barbara L Fallon; Vera D Rinaldi; Teresa L Southard; Charles M Perou; John C Schimenti
Journal:  Genetics       Date:  2012-07-30       Impact factor: 4.562

5.  KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.

Authors:  J Stebbing; H Zhang; Y Xu; L C Lit; A R Green; A Grothey; Y Lombardo; M Periyasamy; K Blighe; W Zhang; J A Shaw; I O Ellis; H J Lenz; G Giamas
Journal:  Oncogene       Date:  2014-06-09       Impact factor: 9.867

6.  SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1.

Authors:  H Zhang; Y Xu; A Filipovic; L C Lit; C-Y Koo; J Stebbing; G Giamas
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

7.  Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

Authors:  L Benhaim; W Zhang; T Wakatsuki; D Yang; A Gerger; P Bohanes; D Paez; F Loupakis; M J LaBonte; Y Ning; R El-Khoueiry; R Ladner; P Wilson; H Zhang; G Giamas; J Stebbing; H J Lenz
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

Review 8.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

9.  Mitogen-Activated Protein (MAP) Kinase Scaffolding Proteins: A Recount.

Authors:  Melanie Meister; Ana Tomasovic; Antje Banning; Ritva Tikkanen
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

10.  Slt2p phosphorylation induces cyclin C nuclear-to-cytoplasmic translocation in response to oxidative stress.

Authors:  Chunyan Jin; Randy Strich; Katrina F Cooper
Journal:  Mol Biol Cell       Date:  2014-02-19       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.